Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5735 | Andrographolide |
| Andrographolide is an antiinflammatory, antiviral, anti-cancer , hepatoprotective, antithrombotic, hypotensive and antiatherosclerotic drug, it can cure hyperpigmentation disorders. Andrographolide protects against chemical-induced oxidative damage by up-regulating the gene transcription and activity of antioxidant enzymes in various tissues.Andrographolide has potential as a leading compound in the prevention or treatment of obesity and insulin resistance, can ameliorate lipid metabolism and improve glucose use in mice with HFD-induced obesity. | |
| BCN5738 | Paeonol |
| Paeonol has anticancer, anti-inflammatory, antioxidant and cardiovascular protective activities, it shows a novel inhibitory role on neuroinflammation, and presents a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases. Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively; it inhibits PGE₂ synthesis and COX-2 expression, and modulates Sirtuin 1, PKCδ and c-Src signaling pathway. | |
| BCN5740 | Costunolide |
| Costunolide has antipyretic, anti-inflammatory, anti-oxidant, anti-carcinogenic and anti-fungal activities, it possesses normo-glycemic and hypolipidemic activity. Costunolide inhibits RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity; it inhibits IL-1beta gene expression by blocking the activation of MAPKs and DNA binding of AP-1; it also induces the ROS-mediated mitochondrial permeability transition and resultant cytochrome c release, | |
| BCN5742 | Mollugin |
| Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Mollugin has anticancer efficacy, can modulate the HER2, HO-1, Nrf2 , and NF- κB pathways. | |
| BCN5743 | Myriceric acid B |
| 1. Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41 and can serve as a lead compound for developing novel anti-HIV-1 drug. 2. Myriceric acid B scavenges DPPH free radicals with IC50 value of 21.8 uM, it inhibits aromatase activity with IC50 value of 6.8 uM, it also exhibits cytotoxic activity towards the MOLT-3 cell line with IC50 values of 3.9 uM. | |
